Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 01, 2023 09:00 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio

Tel Aviv, Israel / Vancouver, Canada, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on...
July 17, 2023 16:15 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Announces Share-Based Payment for the Company's Consultants

Tel Aviv, Israel / Vancouver, Canada, July 17, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on...
July 11, 2023 08:30 ET | Source: Clearmind Medicine Inc.

Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board

Tel Aviv, Israel/Vancouver, Canada, July 11, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery...
June 16, 2023 09:05 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome

The treatment combines Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions, and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of its proprietary...
June 09, 2023 09:30 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity

The conference will stream live on Monday, June 12, at 10:00 AM EST Tel Aviv, Israel / Vancouver, Canada, June 09, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE:...
May 22, 2023 08:30 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder

Tel Aviv, Israel / Vancouver, Canada, May 22, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery...
May 19, 2023 16:15 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Tel Aviv, Israel / Vancouver, Canada, May 19, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a biotech company focused on...
May 17, 2023 09:00 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity

The conference will stream live on Monday, June 12, at 10:00 AM EST Tel Aviv, Israel / Vancouver, Canada, May 17, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND),...
May 12, 2023 09:00 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder

IMCA medical center's ethics committee approves clinical trial using proprietary CMND-100 treatment in Israel Tel Aviv, Israel / Vancouver, Canada, May 12, 2023 (GLOBE NEWSWIRE) -- Clearmind...
May 09, 2023 16:15 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces Granting of Stock and Warrants

Tel Aviv, Israel / Vancouver, Canada, May 09, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right